8/104 sources · 4 publishersUpdated Oct 21, 14:33 UTC
Jaguar Health’s crofelemer cuts infant parenteral support by 15% and targets NDA filing in mid‑2027
Jaguar Health’s subsidiary Napo Pharmaceuticals treated an infant with congenital sodium diarrhea caused by a GUCY2C mutation using oral crofelemer. The therapy lowered the child’s daily parenteral support needs by about 15% within weeks. Jaguar said it will file a New Drug Application for crofelemer in microvillus inclusion disease in mid‑2027, using data from an ongoing pivotal trial.
Why it matters
The company expects the NDA filing could lead to FDA approval, enabling commercialization of crofelemer for rare pediatric intestinal‑failure disorders and potentially expanding its revenue base.
Key facts
- 1Crofelemer reduced the infant’s daily parenteral support needs by approximately 15% within several weeks. stocktitan.net
- 2The infant’s condition is congenital sodium diarrhea caused by a GUCY2C gene mutation. stocktitan.net
- 3Jaguar plans to file a New Drug Application for crofelemer in microvillus inclusion disease in mid‑2027. stocktitan.net
- 4The pivotal trial for the NDA has completed enrollment. stocktitan.net
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.